{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:56:12Z","timestamp":1793354172242,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ijbiomac.2018.08.037","type":"journal-article","created":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T02:06:52Z","timestamp":1533780412000},"page":"180-188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"PA","title":["Novel vaccine candidates against Mycobacterium tuberculosis"],"prefix":"10.1016","volume":"120","author":[{"given":"Saeed","family":"Khoshnood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Heidary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehri","family":"Haeili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Drancourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davood","family":"Darban-Sarokhalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Javad","family":"Nasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Lohrasbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2018.08.037_bb0005","series-title":"World Malaria Report 2015","author":"Organization WH","year":"2016"},{"key":"10.1016\/j.ijbiomac.2018.08.037_bb0010","series-title":"Global Tuberculosis Report","article-title":"Global tuberculosis report 2017","author":"Organization WH","year":"2017"},{"issue":"3","key":"10.1016\/j.ijbiomac.2018.08.037_bb0015","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/trstmh\/trw006","article-title":"Drug-resistant TB: deadly, costly and in need of a vaccine","volume":"110","author":"Manjelievskaia","year":"2016","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"issue":"9979","key":"10.1016\/j.ijbiomac.2018.08.037_bb0020","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0140-6736(15)60570-0","article-title":"WHO's new end TB strategy","volume":"385","author":"Uplekar","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2018.08.037_bb0025","series-title":"Part 2: Background Rates of Adverse Events Following Immunization","article-title":"Supplementary information on vaccine safety","author":"Organization WH","year":"2000"},{"issue":"2","key":"10.1016\/j.ijbiomac.2018.08.037_bb0030","first-page":"66","article-title":"BCG adenitis\u2014need for increased awareness","volume":"18","author":"Govindarajan","year":"2011","journal-title":"The Malaysian journal of medical sciences: MJMS."},{"issue":"2","key":"10.1016\/j.ijbiomac.2018.08.037_bb0035","first-page":"84","article-title":"Complications of bacille Calmette-Guerin (BCG) vaccination and immunotherapy and their management","volume":"1","author":"Grange","year":"1998","journal-title":"Commun. Dis. Public Health"},{"key":"10.1016\/j.ijbiomac.2018.08.037_bb0040","series-title":"DNA Vaccines","first-page":"171","article-title":"Prime-boost strategies in DNA vaccines","author":"Dale","year":"2006"},{"issue":"4","key":"10.1016\/j.ijbiomac.2018.08.037_bb0045","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1086\/341901","article-title":"New vaccines for the prevention of tuberculosis","volume":"35","author":"Fordham von Reyn","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2018.08.037_bb0050","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/395626","article-title":"A Mycobacterium bovis BCG-naked DNA prime-boost vaccination strategy induced CD4","volume":"2014","author":"Lu","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1016\/j.ijbiomac.2018.08.037_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/srep25837","article-title":"Boosting BCG-primed responses with a subunit Apa vaccine during the waning phase improves immunity and imparts protection against Mycobacterium tuberculosis","volume":"6","author":"Nandakumar","year":"2016","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.ijbiomac.2018.08.037_bb0060","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1586\/erv.12.94","article-title":"Prime\u2013boost approaches to tuberculosis vaccine development","volume":"11","author":"Dalmia","year":"2012","journal-title":"Expert Rev. Vaccines"},{"issue":"3","key":"10.1016\/j.ijbiomac.2018.08.037_bb0065","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00430-011-0188-z","article-title":"A DNA vaccine expressing CFP21 and MPT64 fusion protein enhances BCG-induced protective immunity against Mycobacterium tuberculosis infection in mice","volume":"200","author":"Wang","year":"2011","journal-title":"Med. Microbiol. Immunol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2018.08.037_bb0070","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bbamem.2005.10.011","article-title":"Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6, 6\u2032-dibehenate)\u2014a novel adjuvant inducing both strong CMI and antibody responses","volume":"1718","author":"Davidsen","year":"2005","journal-title":"Biochim. Biophys. Acta Biomembr."},{"issue":"52","key":"10.1016\/j.ijbiomac.2018.08.037_bb0075","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1016\/j.vaccine.2014.10.036","article-title":"A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human","volume":"32","author":"van Dissel","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2018.08.037_bb0080","series-title":"New M. tuberculosis Vaccines. United States patent application US 15\/306,239","article-title":"Inventors; Statens Serum Institut (SSI), assignee","author":"Aagaard","year":"2017"},{"issue":"4","key":"10.1016\/j.ijbiomac.2018.08.037_bb0085","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.chom.2008.03.003","article-title":"Mycobacterium tuberculosis prevents inflammasome activation","volume":"3","author":"Master","year":"2008","journal-title":"Cell Host Microbe"},{"issue":"11","key":"10.1016\/j.ijbiomac.2018.08.037_bb0090","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.vaccine.2015.01.058","article-title":"Deletion of zmp1 improves Mycobacterium bovis BCG-mediated protection in a guinea pig model of tuberculosis","volume":"33","author":"Sander","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2018.08.037_bb0095","first-page":"46","article-title":"Production of a viral-vectored vaccine candidate against tuberculosis","volume":"10","author":"Jordan","year":"2012","journal-title":"BioProcess Int."},{"key":"10.1016\/j.ijbiomac.2018.08.037_bb0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.imlet.2017.07.007","article-title":"Tissue plasminogen activator (tPA) signal sequence enhances immunogenicity of MVA-based vaccine against tuberculosis","volume":"190","author":"Kou","year":"2017","journal-title":"Immunol. Lett."},{"issue":"9871","key":"10.1016\/j.ijbiomac.2018.08.037_bb0105","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2018.08.037_bb0110","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/thoraxjnl-2014-205202","article-title":"TB vaccine development: where are we and why is it so difficult?","volume":"70","author":"Wilkie","year":"2015","journal-title":"Thorax"},{"issue":"11","key":"10.1016\/j.ijbiomac.2018.08.037_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143552","article-title":"A novel MVA-based multiphasic vaccine for prevention or treatment of tuberculosis induces broad and multifunctional cell-mediated immunity in mice and primates","volume":"10","author":"Leung-Theung-Long","year":"2015","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.ijbiomac.2018.08.037_bb0120","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(14)70845-X","article-title":"Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial","volume":"14","author":"Satti","year":"2014","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.ijbiomac.2018.08.037_bb0125","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3390\/vaccines2020463","article-title":"Novel GMO-based vaccines against tuberculosis: state of the art and biosafety considerations","volume":"2","author":"Leunda","year":"2014","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.ijbiomac.2018.08.037_bb0130","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/01.qco.0000168380.08895.9a","article-title":"Recent developments in tuberculosis vaccines","volume":"18","author":"Haile","year":"2005","journal-title":"Curr. Opin. Infect. Dis."},{"issue":"42","key":"10.1016\/j.ijbiomac.2018.08.037_bb0135","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1016\/j.vaccine.2013.07.051","article-title":"Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials","volume":"31","author":"Arbues","year":"2013","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.ijbiomac.2018.08.037_bb0140","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/14760584.2017.1324303","article-title":"MTBVAC from discovery to clinical trials in tuberculosis-endemic countries","volume":"16","author":"Marinova","year":"2017","journal-title":"Expert Rev. Vaccines"},{"issue":"5","key":"10.1016\/j.ijbiomac.2018.08.037_bb0145","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/infdis\/jix030","article-title":"Revaccination of guinea pigs with the live attenuated mycobacterium tuberculosis vaccine MTBVAC improves BCG's protection against tuberculosis","volume":"216","author":"Clark","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2018.08.037_bb0150","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms16085","article-title":"Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis","volume":"8","author":"Aguilo","year":"2017","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.ijbiomac.2018.08.037_bb0155","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/cid\/cir951","article-title":"Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis","volume":"54","author":"Andrews","year":"2012","journal-title":"Clin. Infect. Dis."},{"issue":"40","key":"10.1016\/j.ijbiomac.2018.08.037_bb0160","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1016\/j.vaccine.2014.07.047","article-title":"Hyper-attenuated MTBVAC erp mutant protects against tuberculosis in mice","volume":"32","author":"Solans","year":"2014","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.ijbiomac.2018.08.037_bb0165","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1099\/vir.0.81956-0","article-title":"Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER. C6 cells","volume":"87","author":"Havenga","year":"2006","journal-title":"J. Gen. Virol."},{"issue":"48","key":"10.1016\/j.ijbiomac.2018.08.037_bb0170","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1016\/j.vaccine.2015.10.017","article-title":"Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A","volume":"33","author":"Stylianou","year":"2015","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.ijbiomac.2018.08.037_bb0175","doi-asserted-by":"crossref","first-page":"6357","DOI":"10.4049\/jimmunol.173.10.6357","article-title":"Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis","volume":"173","author":"Wang","year":"2004","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.ijbiomac.2018.08.037_bb0180","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1128\/IAI.00517-06","article-title":"Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis","volume":"74","author":"Santosuosso","year":"2006","journal-title":"Infect. Immun."},{"issue":"6","key":"10.1016\/j.ijbiomac.2018.08.037_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005856","article-title":"Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis","volume":"4","author":"Xing","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2018.08.037_bb0190","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.tube.2016.05.013","article-title":"TB vaccines in clinical development","volume":"99","author":"Ginsberg","year":"2016","journal-title":"Tuberculosis"},{"issue":"2","key":"10.1016\/j.ijbiomac.2018.08.037_bb0195","doi-asserted-by":"crossref","first-page":"196","DOI":"10.5114\/ceji.2017.69362","article-title":"Vaccine research and development: tuberculosis as a global health threat","volume":"42","author":"Usman","year":"2017","journal-title":"Central-European journal of immunology."},{"issue":"5","key":"10.1016\/j.ijbiomac.2018.08.037_bb0200","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1586\/erv.11.28","article-title":"Tuberculosis vaccines in clinical trials","volume":"10","author":"Rowland","year":"2011","journal-title":"Expert Rev. Vaccines"},{"issue":"26","key":"10.1016\/j.ijbiomac.2018.08.037_bb0205","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1016\/j.vaccine.2016.02.079","article-title":"Status of vaccine research and development of vaccines for tuberculosis","volume":"34","author":"Evans","year":"2016","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.ijbiomac.2018.08.037_bb0210","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.vaccine.2004.09.008","article-title":"Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis","volume":"23","author":"Cardona","year":"2005","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.ijbiomac.2018.08.037_bb0215","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1365-3083.2009.02251.x","article-title":"Effectiveness and safety of a treatment regimen based on isoniazid plus vaccination with Mycobacterium tuberculosis cells' fragments: field-study with naturally mycobacterium caprae-infected goats","volume":"69","author":"Domingo","year":"2009","journal-title":"Scand. J. Immunol."},{"issue":"11","key":"10.1016\/j.ijbiomac.2018.08.037_bb0220","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1128\/CVI.00255-08","article-title":"Enhanced gamma interferon responses of mouse spleen cells following immunotherapy for tuberculosis relapse","volume":"15","author":"Gil","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2018.08.037_bb0225","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.vaccine.2009.09.134","article-title":"Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI\u00ae","volume":"28","author":"Vilaplana","year":"2010","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.ijbiomac.2018.08.037_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020404","article-title":"Prophylactic effect of a therapeutic vaccine against TB based on fragments of Mycobacterium tuberculosis","volume":"6","author":"Vilaplana","year":"2011","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.ijbiomac.2018.08.037_bb0235","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1016\/j.vaccine.2010.02.094","article-title":"Ag85B\u2013ESAT-6 adjuvanted with IC31\u00ae promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in na\u00efve human volunteers","volume":"28","author":"van Dissel","year":"2010","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.ijbiomac.2018.08.037_bb0240","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/eji.200737889","article-title":"Protective anti-mycobacterial T cell responses through exquisite in vivo activation of vaccine-targeted dendritic cells","volume":"38","author":"Kamath","year":"2008","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2018.08.037_bb0245","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1586\/14760584.6.5.741","article-title":"IC31\u00ae and IC30, novel types of vaccine adjuvant based on peptide delivery systems","volume":"6","author":"Lingnau","year":"2007","journal-title":"Expert Rev. Vaccines"},{"issue":"26","key":"10.1016\/j.ijbiomac.2018.08.037_bb0250","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1016\/j.vaccine.2006.03.072","article-title":"Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31","volume":"24","author":"Agger","year":"2006","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.ijbiomac.2018.08.037_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003683","article-title":"Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31\u00ae adjuvant","volume":"3","author":"Kamath","year":"2008","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ijbiomac.2018.08.037_bb0260","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13063-017-2354-0","article-title":"A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1\/IC31\u00ae in people living in a TB-endemic area","volume":"19","author":"Hussein","year":"2018","journal-title":"Trials"},{"issue":"12","key":"10.1016\/j.ijbiomac.2018.08.037_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114602","article-title":"Safety and immunogenicity of H1\/IC31\u00ae, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells\/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial","volume":"9","author":"Reither","year":"2014","journal-title":"PLoS One"},{"issue":"33","key":"10.1016\/j.ijbiomac.2018.08.037_bb0270","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1016\/j.vaccine.2015.06.051","article-title":"First-in-human trial of the post-exposure tuberculosis vaccine H56: IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults","volume":"33","author":"Luabeya","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.ijbiomac.2018.08.037_bb0275","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1172\/JCI46252","article-title":"The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection","volume":"122","author":"Lin","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijbiomac.2018.08.037_bb0280","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jpba.2018.05.048","article-title":"Tuberculosis vaccine candidate: characterization of H4-IC31 formulation and H4 antigen conformation","volume":"57","author":"Deshmukh","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"6","key":"10.1016\/j.ijbiomac.2018.08.037_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039909","article-title":"The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity","volume":"7","author":"Billeskov","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ijbiomac.2018.08.037_bb0290","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.vaccine.2017.01.055","article-title":"Safety and immunogenicity of the novel H4: IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: two phase I dose escalation trials","volume":"35","author":"Norrby","year":"2017","journal-title":"Vaccine"},{"issue":"30","key":"10.1016\/j.ijbiomac.2018.08.037_bb0295","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1016\/j.vaccine.2015.05.036","article-title":"The tuberculosis vaccine H4: IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: a randomized controlled trial","volume":"33","author":"Geldenhuys","year":"2015","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.ijbiomac.2018.08.037_bb0300","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-2600(18)30077-8","article-title":"Safety and immunogenicity of the novel tuberculosis vaccine ID93+ GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial","volume":"6","author":"Penn-Nicholson","year":"2018","journal-title":"Lancet Respir. Med."},{"issue":"4","key":"10.1016\/j.ijbiomac.2018.08.037_bb0305","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1080\/21645515.2015.1120393","article-title":"Current status of new tuberculosis vaccine in children","volume":"12","author":"Pang","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"issue":"5","key":"10.1016\/j.ijbiomac.2018.08.037_bb0310","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.4049\/jimmunol.1301161","article-title":"Protection against tuberculosis with homologous or heterologous protein\/vector vaccine approaches is not dependent on CD8+ T cells","volume":"191","author":"Baldwin","year":"2013","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.ijbiomac.2018.08.037_bb0315","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1128\/CVI.00372-14","article-title":"The ID93 tuberculosis vaccine candidate does not induce sensitivity to purified protein derivative","volume":"21","author":"Baldwin","year":"2014","journal-title":"Clin. Vaccine Immunol."},{"issue":"19","key":"10.1016\/j.ijbiomac.2018.08.037_bb0320","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.vaccine.2016.03.029","article-title":"Pulmonary immunity and durable protection induced by the ID93\/GLA-SE vaccine candidate against the hyper-virulent Korean Beijing Mycobacterium tuberculosis strain K","volume":"34","author":"Cha","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2018.08.037_bb0325","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3389\/fimmu.2017.01147","article-title":"The recombinant bacille calmette\u2013gu\u00e9rin vaccine VPM1002: ready for clinical efficacy testing","volume":"8","author":"Nieuwenhuizen","year":"2017","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.ijbiomac.2018.08.037_bb0330","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1172\/JCI24617","article-title":"Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin","volume":"115","author":"Grode","year":"2005","journal-title":"J. Clin. Investig."},{"issue":"52","key":"10.1016\/j.ijbiomac.2018.08.037_bb0335","doi-asserted-by":"crossref","first-page":"7608","DOI":"10.1016\/j.vaccine.2012.10.031","article-title":"The recombinant tuberculosis vaccine rBCG \u0394ureC: hly+ induces apoptotic vesicles for improved priming of CD4+ and CD8+ T cells","volume":"30","author":"Farinacci","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.ijbiomac.2018.08.037_bb0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152200","article-title":"High sequence variability of the ppE18 gene of clinical Mycobacterium tuberculosis complex strains potentially impacts effectivity of vaccine candidate M72\/AS01E","volume":"11","author":"Homolka","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ijbiomac.2018.08.037_bb0345","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.tube.2014.07.001","article-title":"Safety and immunogenicity of the M72\/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial","volume":"94","author":"Idoko","year":"2014","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ijbiomac.2018.08.037_bb0350","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.tube.2016.07.005","article-title":"Safety and immunogenicity of the M72\/AS01E candidate tuberculosis vaccine in adults with tuberculosis: a phase II randomised study","volume":"100","author":"Gillard","year":"2016","journal-title":"Tuberculosis"},{"issue":"32","key":"10.1016\/j.ijbiomac.2018.08.037_bb0355","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.vaccine.2015.05.088","article-title":"Safety and immunogenicity of candidate vaccine M72\/AS01 E in adolescents in a TB endemic setting","volume":"33","author":"Penn-Nicholson","year":"2015","journal-title":"Vaccine"},{"issue":"26","key":"10.1016\/j.ijbiomac.2018.08.037_bb0360","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1016\/j.vaccine.2015.03.056","article-title":"Developing whole mycobacteria cell vaccines for tuberculosis: workshop proceedings, Max Planck Institute for Infection Biology, Berlin, Germany, July 9, 2014","volume":"33","author":"Kaufmann","year":"2015","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.ijbiomac.2018.08.037_bb0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168521","article-title":"Immunogenicity and protective efficacy of the DAR-901 booster vaccine in a murine model of tuberculosis","volume":"11","author":"Lahey","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ijbiomac.2018.08.037_bb0370","doi-asserted-by":"crossref","DOI":"10.1038\/cmi.2009.9","article-title":"Immunotherapeutical potential of Mycobacterium vaccae on M. tuberculosis infection in mice","volume":"6","author":"Xu","year":"2009","journal-title":"Cell. Mol. Immunol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2018.08.037_bb0375","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0264-410X(90)90002-4","article-title":"Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis","volume":"8","author":"Stanford","year":"1990","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.ijbiomac.2018.08.037_bb0380","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1600324113","article-title":"Immunization with a heat-killed preparation of the environmental bacterium Mycobacterium vaccae promotes stress resilience in mice","volume":"113","author":"Reber","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/j.ijbiomac.2018.08.037_bb0385","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023826","article-title":"Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis","volume":"6","author":"Yang","year":"2011","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ijbiomac.2018.08.037_bb0390","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1128\/iai.65.8.3317-3327.1997","article-title":"Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection","volume":"65","author":"Hernandez-Pando","year":"1997","journal-title":"Infect. Immun."},{"issue":"6","key":"10.1016\/j.ijbiomac.2018.08.037_bb0395","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1053\/rmed.2001.1065","article-title":"Does immunotherapy with heat-killed Mycobacterium vaccae offer hope for the treatment of multi-drug-resistant pulmonary tuberculosis?","volume":"95","author":"Stanford","year":"2001","journal-title":"Respir. Med."},{"issue":"2","key":"10.1016\/j.ijbiomac.2018.08.037_bb0400","first-page":"85","article-title":"Immunotherapeutic effect of Mycobacterium vaccae on multi-drug resistant pulmonary tuberculosis","volume":"23","author":"Luo","year":"2000","journal-title":"Zhonghua jie he he hu xi za zhi\u202f=\u202fZhonghua jiehe he huxi zazhi\u202f=\u202fChinese journal of tuberculosis and respiratory diseases"},{"issue":"Supplement_3","key":"10.1016\/j.ijbiomac.2018.08.037_bb0405","doi-asserted-by":"crossref","DOI":"10.1086\/313880","article-title":"Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis","volume":"30","author":"Waddell","year":"2000","journal-title":"Clin. Infect. Dis."},{"issue":"16","key":"10.1016\/j.ijbiomac.2018.08.037_bb0410","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1097\/00002030-200311070-00010","article-title":"Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial","volume":"17","author":"Vuola","year":"2003","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.ijbiomac.2018.08.037_bb0415","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/QAD.0b013e3283350f1b","article-title":"Prevention of tuberculosis in Bacille Calmette\u2013Gu\u00e9rin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine","volume":"24","author":"von Reyn","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.ijbiomac.2018.08.037_bb0420","first-page":"1","article-title":"The current status, challenges, and future developments of new tuberculosis vaccines","author":"Gong","year":"2018","journal-title":"Hum. Vaccin. Immunother."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014181301833215X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014181301833215X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T07:10:33Z","timestamp":1758870633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014181301833215X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":84,"alternative-id":["S014181301833215X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2018.08.037","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel vaccine candidates against Mycobacterium tuberculosis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2018.08.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}